argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia https://drumup.io/s/stnpuV
By (@AvatarNemo) argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia https://drumup.io/s/stnpuV Source:: https://twitter.com/AvatarNemo/status/1070232812601495552





























